Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | MMP2 | P08253 | 2/20 | 0.54 |
| ▸ | MMP1 | P03956 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.52 |
| ▸ | IL1RN | P18510 | 1/20 | 0.52 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3246013 | 0.79 | CA2 (0.52) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL2468179 | 0.79 | MMP2 (0.52) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL299247 | 0.79 | CA1 (0.52) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL4911074 | 0.79 | CA1 (0.52) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL423687 | 0.77 | CA2 (0.57) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL9135655 | 0.77 | MMP2 (0.57) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL78504 | 0.77 | GAA (0.59) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL423264 | 0.77 | CA1 (0.57) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL6934611 | 0.77 | CA1 (0.57) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL426036 | 0.76 | PSEN1 (0.49) | CA1CA2ALDH1A1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1319 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144784-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-05-12 | — | — | US | claimed |
| US-20180282289-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-10-04 | — | — | US | claimed |
| EP-3380970-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | Sanford Burnham Prebys Medical Discovery Institute (US) | 2018-10-03 | — | — | EP | claimed |
| EP-2933248-B1 | NOVEL RENIN INHIBITOR | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-01-31 | — | — | EP | claimed |
| US-9758480-B2 | 1-(cycloalkyl-carbonyl)proline derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-09-12 | — | — | US | claimed |
| US-9556159-B2 | Renin inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-31 | — | — | US | claimed |
| US-20150344877-A1 | METHODS FOR TREATING VIRAL INFECTIONS | PTC THERAPEUTICS, INC. (US) | 2015-12-03 | — | — | US | claimed |
| EP-2933248-A1 | NOVEL RENIN INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-10-21 | — | — | EP | claimed |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-08-20 | — | — | US | claimed |
| US-20150210640-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-07-30 | — | — | US | claimed |
| US-4968695-A | NEMATOCIDES, LARVICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1990-11-06 | — | — | US | claimed |
| EP-0392317-A2 | Benzimidazoles, drugs containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1990-10-17 | — | — | EP | claimed |
| EP-0335315-A1 | New alkanephenones | CIBA-GEIGY AG (CH) | 1989-10-04 | — | — | EP | claimed |
| US-4845106-A | INSECTICIDES | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1989-07-04 | — | — | US | claimed |
| EP-0292822-A2 | Substituted nitroalkenes | BAYER AG (DE) | 1988-11-30 | — | — | EP | claimed |
| EP-0272671-A2 | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors | SANDOZ LTD. (CH) | 1988-06-29 | — | — | EP | claimed |
| US-4742060-A | 2-(NITROIMINO)- OR 2-(NITROMETHYLENE)-IMIDAZOLIDINES AS INSECTICIDES | NIHON TOKUSHU NOYAKU SEIZO K. K. (JP) | 1988-05-03 | — | — | US | claimed |
| US-4410522-A | BACTERICIDES | TOYAMA CHEMICAL CO., LTD. (JP) | 1983-10-18 | — | — | US | claimed |
| US-4327097-A | BACTERICIDES FOR MAMMALS | TOYAMA CHEMICAL CO., LTD. (JP) | 1982-04-27 | — | — | US | claimed |
| US-4219554-A | Novel penicillins and cephalosporins and process for producing same | TOYAMA CHEMICAL COMPANY, LIMITED (JP) | 1980-08-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | REN, AGTR1, ACE | CA1 1845/4885CA2 64/4885MMP2 118/4885 |
| US-20150210640-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | RB1, F2, SFPQ | CA1 2538/4885CA2 1703/4885MMP2 1391/4885 |
| US-20220144784-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | APLNR, AGTR1, AGTR2 | CA1 2295/4885CA2 436/4885MMP2 2536/4885 |
| US-20180282289-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | APLNR, AGTR1, AGTR2 | CA1 2276/4885CA2 438/4885MMP2 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.